- Home
- HYI vs NYXH Comparison
HYI vs NYXH Comparison
Compare HYI & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYI
- NYXH
- Stock Information
- Founded
- HYI 2010
- NYXH 2009
- Country
- HYI United States
- NYXH Belgium
- Employees
- HYI N/A
- NYXH N/A
- Industry
- HYI Investment Managers
- NYXH Medical/Dental Instruments
- Sector
- HYI Finance
- NYXH Health Care
- Exchange
- HYI Nasdaq
- NYXH Nasdaq
- Market Cap
- HYI 264.3M
- NYXH 222.3M
- IPO Year
- HYI N/A
- NYXH 2021
- Fundamental
- Price
- HYI $11.79
- NYXH $7.71
- Analyst Decision
- HYI
- NYXH Strong Buy
- Analyst Count
- HYI 0
- NYXH 4
- Target Price
- HYI N/A
- NYXH $14.50
- AVG Volume (30 Days)
- HYI 50.6K
- NYXH 135.0K
- Earning Date
- HYI 01-01-0001
- NYXH 05-14-2025
- Dividend Yield
- HYI 9.59%
- NYXH N/A
- EPS Growth
- HYI N/A
- NYXH N/A
- EPS
- HYI N/A
- NYXH N/A
- Revenue
- HYI N/A
- NYXH $4,716,818.00
- Revenue This Year
- HYI N/A
- NYXH $323.07
- Revenue Next Year
- HYI N/A
- NYXH $204.30
- P/E Ratio
- HYI N/A
- NYXH N/A
- Revenue Growth
- HYI N/A
- NYXH N/A
- 52 Week Low
- HYI $10.99
- NYXH $5.55
- 52 Week High
- HYI $12.24
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- HYI 53.23
- NYXH 59.14
- Support Level
- HYI $11.76
- NYXH $7.52
- Resistance Level
- HYI $11.86
- NYXH $8.00
- Average True Range (ATR)
- HYI 0.10
- NYXH 0.51
- MACD
- HYI 0.00
- NYXH 0.06
- Stochastic Oscillator
- HYI 67.50
- NYXH 63.95
About HYI Western Asset High Yield Defined Opportunity Fund Inc.
Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. It invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.